-
公开(公告)号：US11692216B2
公开(公告)日：2023-07-04
申请号：US16788406
申请日：2020-02-12
发明人： Masaaki Oka , Shoichi Hazama , Ryouichi Tsunedomi
IPC分类号： C12Q1/6886 , C12Q1/6827 , C12Q1/68 , C12Q1/6809 , C12Q1/6876 , G01N33/50
CPC分类号： C12Q1/6827 , C12Q1/68 , C12Q1/6809 , C12Q1/6876 , G01N33/5014 , C12Q2600/106 , C12Q2600/118 , C12Q2600/142 , C12Q2600/156 , C12Q2600/158
摘要： An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR51I2 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.
-
公开(公告)号：US11111526B2
公开(公告)日：2021-09-07
申请号：US16322363
申请日：2017-08-02
发明人： Toshiya Tsuda , Shuichi Kamei , Mitsuyoshi Oba , Hirofumi Yamano , Ryouichi Tsunedomi , Shoichi Hazama , Hiroaki Nagano
IPC分类号： C12Q1/68 , C12Q1/6832 , C07H21/00 , C12N15/09 , C12M1/00
摘要： In the case of using a blocking nucleic acid to prevent non-specific hybridization of a target nucleic acid with a nucleic acid probe, further excellent efficiency of detecting the target nucleic acid is achieved. A buffer composition used in hybridization of a target nucleic acid with a nucleic acid probe, wherein the buffer composition for hybridization contains a blocking nucleic acid comprising a nucleotide sequence complementary to a region comprising at least a non-detection target nucleotide in a non-target nucleic acid, in a concentration of one or more times higher than the concentration of a nucleic acid in a nucleic acid mixture consisting of the target nucleic acid and the non-target nucleic acid.
-
公开(公告)号：US10450601B2
公开(公告)日：2019-10-22
申请号：US15024392
申请日：2014-09-01
IPC分类号： C12Q1/68 , C07H21/00 , C12Q1/6837 , C12N15/09 , C12Q1/6816 , C12Q1/6832
摘要： A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.
-
公开(公告)号：US11384385B2
公开(公告)日：2022-07-12
申请号：US16624469
申请日：2018-06-22
IPC分类号： C12Q1/6827 , C12Q1/6876
摘要： A therapeutic effect of irinotecan is predicted using a predetermined genetic polymorphism. A genetic polymorphism identified by rs1980576 in APCDD1L gene, or a genetic polymorphism in linkage disequilibrium with the above genetic polymorphism is analyzed, and determination is performed based on the genotype of the genetic polymorphism.
-
公开(公告)号：US20200172966A1
公开(公告)日：2020-06-04
申请号：US16788406
申请日：2020-02-12
发明人： Masaaki Oka , Shoichi Hazama , Ryouichi Tsunedomi
IPC分类号： C12Q1/6827 , G01N33/50 , C12Q1/6876 , C12Q1/6809 , C12Q1/68
摘要： An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR5112 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.
-
公开(公告)号：US11670398B2
公开(公告)日：2023-06-06
申请号：US16613507
申请日：2018-05-18
发明人： Hideyasu Matsuyama , Yoshihiko Hamamoto , Yusuke Fujita , Yoshiaki Yamamoto , Ryouichi Tsunedomi , Mitsuyoshi Oba , Hirofumi Yamano , Yukiha Ishikawa
摘要： It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.
-
公开(公告)号：US20210158893A1
公开(公告)日：2021-05-27
申请号：US16613507
申请日：2018-05-18
发明人： Hideyasu Matsuyama , Yoshihiko Hamamoto , Yusuke Fujita , Yoshiaki Yamamoto , Ryouichi Tsunedomi , Mitsuyoshi Oba , Hirofumi Yamano , Yukiha Ishikawa
摘要： It is intended to conveniently determine the pharmacokinetics of axitinib and to predict the therapeutic effect of axitinib. The present invention provides a method for determining the pharmacokinetics of axitinib, comprising the step of calculating a predicted pharmacokinetic parameter of axitinib using specific gene polymorphisms and background factors regarding a test subject.
-
公开(公告)号：US20180237833A1
公开(公告)日：2018-08-23
申请号：US15549823
申请日：2016-02-16
发明人： Masaaki Oka , Shoichi Hazama , Ryouichi Tsunedomi
IPC分类号： C12Q1/6827 , C12Q1/6809 , C12Q1/6876 , G01N33/50
CPC分类号： C12Q1/6827 , C12Q1/6809 , C12Q1/6876 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/142 , C12Q2600/156 , C12Q2600/158 , G01N33/5014
摘要： An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR5112 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.
-
公开(公告)号：US20160265037A1
公开(公告)日：2016-09-15
申请号：US15024392
申请日：2014-09-01
发明人： Shuichi Kamei , Mayuko Hosoya , Masaki Oka , Shoichi Hazama , Ryouichi Tsunedomi
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6837 , C12N15/09 , C12Q1/68 , C12Q1/6816 , C12Q1/6832 , C12Q2527/107 , C12Q2527/125
摘要： A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.
摘要翻译： 提供了用于靶核酸杂交的缓冲组合物。 核酸可以包括用核酸探针检测的核苷酸。 探针可以含有与靶核酸互补的核苷酸序列。 缓冲液可以包括具有与非靶核酸互补的核苷酸序列的阻断核酸，其具有对应于待检测核苷酸的不被检测的核苷酸。 即使存在非靶核酸，缓冲组合物也可以抑制与核酸探针的非特异性杂交。 使用缓冲组合物可以实现目标核酸的优异检测效率。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.018 秒)
